Momenta Pharmaceuticals Company Profile (NASDAQ:MNTA)

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.

Industry, Sector and Symbol:

Sector: Medical
Industry: Drugs - Generic
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: MNTA
CUSIP: 60877T10

Key Metrics:

Previous Close: $11.86
50 Day Moving Average: $12.01
200 Day Moving Average: $10.78
52-Week Range: $7.86 - $18.85
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -12.10
P/E Growth: 0.00
Market Cap: $813.56M
Outstanding Shares: 68,597,000
Beta: 1.97

Profitability:

Net Margins: -126.37%
Return on Equity: -28.76%
Return on Assets: -24.23%

Debt:

Current Ratio: 8.36%
Quick Ratio: 8.36%

Additional Links:

Companies Related to Momenta Pharmaceuticals:

Consensus Ratings for Momenta Pharmaceuticals (NASDAQ:MNTA) (?)

Ratings Breakdown:	1 Sell Rating, 3 Hold Ratings, 4 Buy Ratings
Consensus Rating:	Hold (Score: 2.38)
Consensus Price Target:	$16.38 (38.07% upside)

Analysts' Ratings History for Momenta Pharmaceuticals (NASDAQ:MNTA)

Show:

Date	Firm	Action	Rating	Price Target
9/7/2016	Maxim Group	Downgrade	Hold -> Sell	$6.00
8/7/2016	Cowen and Company	Reiterated Rating	Hold
8/5/2016	JPMorgan Chase & Co.	Lower Price Target	Overweight	$21.00 -> $15.00
8/5/2016	Brean Capital	Set Price Target	Buy	$19.00
6/6/2016	Goldman Sachs Group Inc.	Initiated Coverage	Neutral	$14.00
5/4/2016	Leerink Swann	Reiterated Rating	Outperform	$21.00 -> $18.00
2/19/2016	Stifel Nicolaus	Lower Price Target	Buy	$29.00 -> $20.00
11/23/2015	Barclays PLC	Initiated Coverage	Equal Weight	$22.00
8/24/2015	Sanford C. Bernstein	Reiterated Rating	Buy

(Data available from 9/28/2014 forward)

Earnings History for Momenta Pharmaceuticals (NASDAQ:MNTA)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/2/2016
8/4/2016	Q216	($0.32)	($0.31)	$23.55 million	$26.40 million	View	N/A
5/3/2016	Q116	($0.32)	($0.35)	$28.12 million	$19.90 million	View	N/A
2/18/2016	Q415	($0.04)	($0.43)	$30.42 million	$22.40 million	View	Listen
11/4/2015	Q315	($0.19)	($0.44)	$31.76 million	$13.80 million	View	Listen
8/4/2015	Q215	($0.39)	($0.04)	$23.59 million	$44.90 million	View	Listen
5/1/2015	Q115	($0.48)	($0.40)	$11.70 million	$8.60 million	View	N/A
2/17/2015	Q414	($0.26)	($0.31)	$23.80 million	$21.18 million	View	Listen
11/5/2014	Q314	($0.43)	($0.56)	$13.00 million	$9.34 million	View	Listen
7/31/2014	Q214	($0.46)	($0.51)	$11.22 million	$11.00 million	View	Listen
5/6/2014	Q1	($0.55)	($0.53)	$8.41 million	$10.79 million	View	Listen
2/10/2014	Q4	($0.45)	($0.59)	$8.50 million	$12.80 million	View	Listen
11/5/2013	Q313	($0.48)	($0.50)	$8.60 million	$10.80 million	View	N/A
8/1/2013	Q2 2013	($0.45)	($0.57)	$8.85 million	$4.40 million	View	N/A
4/30/2013	Q1 2013	($0.44)	($0.48)	$10.28 million	$7.60 million	View	N/A
2/15/2013	Q4 2012	($0.41)	($0.35)	$10.41 million	$12.70 million	View	N/A
11/7/2012	Q312	($0.27)	($0.51)	$16.48 million	$5.10 million	View	N/A
8/2/2012		($0.17)	($0.20)			View	N/A
5/3/2012		$0.02	($0.10)			View	N/A
2/9/2012		$0.13	($0.02)			View	N/A
11/7/2011		$1.28	$1.18			View	N/A
8/4/2011		$1.21	$1.26			View	N/A
5/5/2011		$0.95	$1.13			View	N/A
2/10/2011		$0.81	$0.77			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Momenta Pharmaceuticals (NASDAQ:MNTA)

Current Year EPS Consensus Estimate: $-1.21 EPS
Next Year EPS Consensus Estimate: $-0.98 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q2 2016	1	($0.36)	($0.36)	($0.36)
Q3 2016	1	($0.34)	($0.34)	($0.34)
Q4 2016	1	($0.29)	($0.29)	($0.29)

(Data provided by Zacks Investment Research)

Dividend History for Momenta Pharmaceuticals (NASDAQ:MNTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Momenta Pharmaceuticals (NASDAQ:MNTA)

Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 81.08%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/22/2016	Bruce Leicher	SVP	Sell	1,030	$12.05	$12,411.50
8/22/2016	Craig A. Wheeler	President	Sell	5,880	$12.02	$70,677.60
8/22/2016	James M Roach	VP	Sell	1,091	$12.05	$13,146.55
8/22/2016	Richard P Shea	CFO	Sell	972	$12.05	$11,712.60
5/20/2016	Bruce Leicher	SVP	Sell	1,000	$10.40	$10,400.00
5/20/2016	Craig A Wheeler	President	Sell	5,880	$10.18	$59,858.40
5/20/2016	Ganesh Venkataraman Kaundinya	VP	Sell	1,050	$10.18	$10,689.00
5/20/2016	Richard P Shea	CFO	Sell	973	$10.18	$9,905.14
5/19/2016	John E Bishop	VP	Sell	784	$10.20	$7,996.80
4/19/2016	John E Bishop	VP	Sell	2,843	$9.57	$27,207.51
2/23/2016	John E Bishop	VP	Sell	329	$9.70	$3,191.30
2/22/2016	Bruce Leicher	SVP	Sell	227	$9.65	$2,190.55
2/22/2016	Craig A Wheeler	President	Sell	1,688	$9.95	$16,795.60
2/22/2016	John E Bishop	VP	Sell	2,848	$9.66	$27,511.68
2/19/2016	Bruce Leicher	SVP	Sell	2,000	$9.64	$19,280.00
2/19/2016	Craig A Wheeler	President	Sell	9,844	$9.37	$92,238.28
2/19/2016	John E. Bishop	VP	Sell	357	$10.28	$3,669.96
2/19/2016	Richard P Shea	CFO	Sell	1,823	$9.64	$17,573.72
2/18/2016	Bruce Leicher	SVP	Sell	337	$10.49	$3,535.13
2/18/2016	James M Roach	VP	Sell	272	$10.49	$2,853.28
2/18/2016	Richard P Shea	CFO	Sell	183	$10.49	$1,919.67
2/17/2016	Craig A Wheeler	President	Sell	1,688	$11.30	$19,074.40
12/11/2015	Michael Franken	Insider	Sell	520	$15.84	$8,236.80
11/20/2015	Craig A Wheeler	President	Sell	1,766	$17.86	$31,540.76
11/19/2015	Craig A Wheeler	President	Sell	2,061	$18.05	$37,201.05
11/17/2015	Craig A Wheeler	President	Sell	1,766	$17.70	$31,258.20
11/5/2015	Craig A. Wheeler	President	Sell	51,667	$18.00	$930,006.00
8/20/2015	Craig A Wheeler	President	Sell	1,766	$22.28	$39,346.48
8/19/2015	Craig A Wheeler	President	Sell	2,061	$22.02	$45,383.22
8/19/2015	James M. Roach	VP	Sell	7,011	$22.09	$154,872.99
8/18/2015	James M Roach	VP	Sell	6,812	$21.80	$148,501.60
8/17/2015	Craig A Wheeler	President	Sell	1,766	$21.77	$38,445.82
7/15/2015	Elizabeth Stoner	Director	Sell	4,570	$22.35	$102,139.50
6/19/2015	John E Bishop	VP	Sell	21,274	$25.50	$542,487.00
6/18/2015	Bruce Leicher	SVP	Sell	20,000	$23.00	$460,000.00
6/18/2015	Craig A Wheeler	President	Sell	155,000	$24.20	$3,751,000.00
6/18/2015	John E Bishop	VP	Sell	36,313	$23.58	$856,260.54
6/4/2015	Craig A Wheeler	President	Sell	103,333	$22.00	$2,273,326.00
6/1/2015	Bruce Leicher	SVP	Sell	40,000	$21.00	$840,000.00
6/1/2015	James M Roach	VP	Sell	25,000	$21.70	$542,500.00
5/20/2015	Craig A Wheeler	President	Sell	1,766	$19.68	$34,754.88
5/19/2015	Craig A Wheeler	President	Sell	2,061	$19.67	$40,539.87
4/23/2015	Craig A Wheeler	President	Sell	51,667	$20.00	$1,033,340.00
4/23/2015	Ganesh Venkataraman Kaundinya	VP	Sell	34,000	$19.95	$678,300.00
4/20/2015	Craig A Wheeler	President	Sell	6,269	$18.75	$117,543.75
4/17/2015	Bruce Leicher	SVP	Sell	52,910	$19.52	$1,032,803.20
4/16/2015	James M Roach	VP	Sell	50,000	$18.70	$935,000.00
3/16/2015	Richard P Shea	CFO	Sell	23,093	$15.10	$348,704.30
3/5/2015	Richard P Shea	CFO	Sell	23,364	$14.90	$348,123.60
2/24/2015	Craig A Wheeler	President	Sell	2,110	$13.52	$28,527.20
2/20/2015	Bruce Leicher	SVP	Sell	1,891	$12.97	$24,526.27
2/20/2015	Craig A Wheeler	President	Sell	9,563	$13.49	$129,004.87
2/20/2015	John E Bishop	VP	Sell	1,768	$12.97	$22,930.96
2/20/2015	Richard P Shea	CFO	Sell	1,812	$12.97	$23,501.64
2/18/2015	Craig A Wheeler	President	Sell	1,688	$11.91	$20,104.08
12/15/2014	Bennett M Shapiro	Director	Sell	5,800	$12.19	$70,702.00
12/11/2014	Michael Franken	Insider	Sell	2,047	$12.29	$25,157.63
12/1/2014	Bennett M Shapiro	Director	Sell	9,903	$12.00	$118,836.00
11/28/2014	Bennett M Shapiro	Director	Sell	1,897	$12.00	$22,764.00
11/25/2014	Craig A Wheeler	President	Sell	2,210	$11.59	$25,613.90
11/20/2014	Craig A Wheeler	President	Sell	1,768	$11.10	$19,624.80
11/17/2014	Craig A Wheeler	President	Sell	1,768	$10.58	$18,705.44
10/3/2014	Bennett M Shapiro	Director	Sell	3,723	$12.00	$44,676.00
9/12/2014	Peter Barton Hutt	Director	Sell	3,640	$11.42	$41,568.80
8/25/2014	Craig A Wheeler	President	Sell	2,209	$11.45	$25,293.05
8/20/2014	Craig A Wheeler	President	Sell	1,768	$11.54	$20,402.72
8/15/2014	Bennett M Shapiro	Director	Sell	3,722	$12.00	$44,664.00
8/15/2014	Craig A Wheeler	President	Sell	1,768	$11.75	$20,774.00
8/13/2014	Bennett M Shapiro	Director	Sell	3,721	$12.00	$44,652.00
5/23/2014	Craig A Wheeler	President	Sell	2,110	$12.06	$25,446.60
5/20/2014	Craig Wheeler	President	Sell	1,688	$12.08	$20,391.04
5/15/2014	Craig Wheeler	President	Sell	1,687	$11.09	$18,708.83
2/25/2014	Craig Wheeler	President	Sell	2,109	$17.47	$36,844.23
2/24/2014	John Bishop	VP	Sell	1,038	$17.67	$18,341.46
2/19/2014	Craig Wheeler	President	Sell	3,797	$17.90	$67,966.30
2/12/2014	Ganesh Venkataraman Kaundinya	VP	Sell	33,000	$17.96	$592,680.00
1/9/2014	John Bishop	VP	Sell	27,159	$19.50	$529,600.50
11/25/2013	Bruce Leicher	SVP	Sell	13,492	$18.00	$242,856.00
11/25/2013	Craig Wheeler	President	Sell	2,215	$17.77	$39,360.55
11/25/2013	Ganesh Venkataraman Kaundinya	VP	Sell	33,211	$18.02	$598,462.22
11/19/2013	Craig Wheeler	President	Sell	2,215	$17.17	$38,031.55
11/15/2013	Craig Wheeler	President	Sell	1,772	$16.88	$29,911.36
10/11/2013	John Bishop	VP	Sell	5,247	$15.46	$81,118.62
8/23/2013	Craig Wheeler	President	Sell	2,109	$14.90	$31,424.10
8/20/2013	Craig Wheeler	President	Sell	2,109	$14.47	$30,517.23
8/15/2013	Craig Wheeler	President	Sell	1,688	$15.43	$26,045.84
7/26/2013	Richard P Shea	CFO	Sell	30,000	$16.61	$498,300.00
6/27/2013	Richard P Shea	CFO	Sell	10,522	$14.61	$153,726.42
6/19/2013	Richard P Shea	CFO	Sell	21,550	$14.61	$314,845.50
5/23/2013	Craig A Wheeler	President	Sell	2,109	$13.03	$27,480.27
5/21/2013	Craig A Wheeler	President	Sell	2,109	$12.83	$27,058.47
5/15/2013	Craig A Wheeler	President	Sell	1,687	$13.33	$22,487.71
3/5/2013	Elizabeth Stoner	Director	Sell	2,040	$14.00	$28,560.00
2/15/2013	Bruce Leicher	SVP	Sell	1,040	$12.26	$12,750.40

(Data available from 1/1/2013 forward)

Latest Headlines for Momenta Pharmaceuticals (NASDAQ:MNTA)

Date	Headline
	Momenta Pharmaceuticals to Regain Global Development and Commercialization Rights to M923, a Proposed Biosimilar of HUMIRA® (adalimumab), Through Termination of Collaboration Agreement with Baxalta, Now Part of Shire (NASDAQ:MNTA) finance.yahoo.com - September 27 at 10:48 AM
	8:01 am Momenta Pharma announces that Shire (SHPG (NASDAQ:MNTA) finance.yahoo.com - September 27 at 10:48 AM
	Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : September 27, 2016 (NASDAQ:MNTA) www.capitalcube.com - September 27 at 10:48 AM
	MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement (NASDAQ:MNTA) biz.yahoo.com - September 27 at 10:48 AM
	Momenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors - GlobeNewswire (press release) (NASDAQ:MNTA) www.globenewswire.com - September 23 at 10:53 AM
	MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:MNTA) biz.yahoo.com - September 23 at 10:53 AM
	Momenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors (NASDAQ:MNTA) www.publicnow.com - September 23 at 10:53 AM
	BIOFACTURA ANNOUNCES ENTRY INTO NON-EXCLUSIVE LICENSE AGREEMENT WITH MOMENTA PHARMACEUTICALS (NASDAQ:MNTA) www.live-pr.com - September 22 at 5:55 PM
	BIOFACTURA ANNOUNCES ENTRY INTO NON-EXCLUSIVE LICENSE AGREEMENT WITH MOMENTA PHARMACEUTICALS (NASDAQ:MNTA) www.live-pr.com - September 22 at 5:55 PM
	Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)'s Expectation Of $297.395 In Sales - Investor Newswire (NASDAQ:MNTA) www.investornewswire.com - September 22 at 10:59 AM
	Momenta Pharmaceuticals Given Average Rating of “Buy” by ... - Petro Global News 24 (NASDAQ:MNTA) petroglobalnews24.com - September 22 at 10:59 AM
	Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) earnings reaction ... - The Independent Republic (NASDAQ:MNTA) theindependentrepublic.com - September 22 at 10:59 AM
	Goldman Sachs Begins Coverage on Momenta Pharmaceuticals, Inc. (MNTA) - DailyQuint (NASDAQ:MNTA) dailyquint.com - September 20 at 11:21 AM
	MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:MNTA) biz.yahoo.com - September 19 at 6:10 PM
	Brokerages Expect Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA ... - DailyQuint (NASDAQ:MNTA) dailyquint.com - September 18 at 10:33 AM
	Momenta Pharmaceuticals : How These Generic Drugs Stocks are Faring? -- Evoke Pharma, Mallinckrodt, Catalyst Pharma, and Momenta Pharma (NASDAQ:MNTA) www.4-traders.com - September 15 at 9:39 AM
	Expected For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Sales Of $297.395 - Investor Newswire (NASDAQ:MNTA) www.investornewswire.com - September 14 at 6:20 PM
	Momenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : September 13, 2016 (NASDAQ:MNTA) www.capitalcube.com - September 14 at 10:28 AM
	Two Things You Must Understand About Biotech Investing (NASDAQ:MNTA) www.fool.com - September 12 at 5:56 PM
	Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : September 12, 2016 (NASDAQ:MNTA) www.capitalcube.com - September 12 at 10:50 AM
	Shares Lower Over the Past Quarter: Momenta Pharmaceuticals Inc ... - Post News (NASDAQ:MNTA) www.kentuckypostnews.com - September 11 at 5:40 PM
	Stock Slipping Down Over the Past Five Trading Sessions: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) - National Daily Press (NASDAQ:MNTA) www.nationaldailypress.com - September 9 at 10:54 AM
	Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Expects Sales Of $297.395 - Investor Newswire (NASDAQ:MNTA) www.investornewswire.com - September 7 at 6:23 PM
	Maxim Group Cuts Rating On Momenta Pharmaceuticals, Inc. (MNTA) - Finance Daily (NASDAQ:MNTA) www.fidaily.com - September 7 at 6:23 PM
	Stock Gapping Down Before the Bell: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) - Post News (NASDAQ:MNTA) www.kentuckypostnews.com - September 7 at 6:23 PM
	Here's Why Maxim Downgraded Momenta Pharmaceuticals, Inc ... - Smarter Analyst (NASDAQ:MNTA) www.smarteranalyst.com - September 7 at 6:23 PM
	Momenta Pharma downgraded by Maxim Group (NASDAQ:MNTA) finance.yahoo.com - September 7 at 9:44 AM
	Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Is Expected To Post EPS Of $-0.66 - RealistInvestor.com (NASDAQ:MNTA) www.realistinvestor.com - September 3 at 10:36 AM
	MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:MNTA) biz.yahoo.com - September 1 at 6:07 PM
	Momenta Pharmaceuticals to Webcast Presentation at the 2016 Wells Fargo Healthcare Conference (NASDAQ:MNTA) finance.yahoo.com - September 1 at 9:20 AM
	Earnings Reaction History: Momenta Pharmaceuticals Inc ... - The Independent Republic (NASDAQ:MNTA) theindependentrepublic.com - August 29 at 6:05 PM
	Momenta Has Momentum After Recent Patent Decision - Seeking Alpha (NASDAQ:MNTA) seekingalpha.com - August 29 at 10:46 AM
	Momenta Pharmaceuticals (MNTA) Jumps: Stock Up 11.3% (NASDAQ:MNTA) finance.yahoo.com - August 25 at 11:19 AM
	Why Momenta Pharmaceuticals Shares Made a Late-Day Jump Higher (NASDAQ:MNTA) www.fool.com - August 24 at 4:51 PM
	Momenta Pharmaceuticals Inc. (MNTA) SVP Sells $12,411.50 in Stock (NASDAQ:MNTA) www.bioportfolio.com - August 24 at 9:20 AM
	Crowd Sentiment & Wall Street Views on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)? - Post News (NASDAQ:MNTA) www.kentuckypostnews.com - August 22 at 10:48 AM
	Analysts See Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Reporting EPS Of $-0.66 - RealistInvestor.com (NASDAQ:MNTA) www.realistinvestor.com - August 20 at 10:18 AM
	MOMENTA PHARMACEUTICALS INC Financials (NASDAQ:MNTA) finance.yahoo.com - August 16 at 6:20 PM
	ETF’s with exposure to Momenta Pharmaceuticals, Inc. : August 15, 2016 (NASDAQ:MNTA) www.capitalcube.com - August 15 at 6:25 PM
	Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:MNTA) www.capitalcube.com - August 12 at 6:18 PM
	Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Records An Estimated Annual Sales Mean Of $297.395 - Investor Newswire (NASDAQ:MNTA) www.investornewswire.com - August 10 at 6:38 PM
	Which way Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) insiders are heading - Review Fortune (NASDAQ:MNTA) reviewfortune.com - August 10 at 9:18 AM
	Despite trial setback, Momenta shares surge on generics news (NASDAQ:MNTA) www.bizjournals.com - August 9 at 6:29 PM
	Despite trial setback, Momenta shares surge on generics news and buyout rumors (NASDAQ:MNTA) www.bizjournals.com - August 8 at 10:54 AM
	Momenta Phama (MNTA) to Cease Further Enrollment in Necuparanib Phase 2 Per IDSMB Recommendation (NASDAQ:MNTA) www.streetinsider.com - August 6 at 9:03 AM
	MOMENTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:MNTA) biz.yahoo.com - August 5 at 6:26 PM
	Why ImmunoGen, Alnylam Pharmaceuticals, and Momenta Pharmaceuticals Rocketed Higher Today (NASDAQ:MNTA) www.fool.com - August 5 at 4:43 PM
	Edited Transcript of MNTA earnings conference call or presentation 4-Aug-16 2:00pm GMT (NASDAQ:MNTA) finance.yahoo.com - August 5 at 9:19 AM
	Pre-Market Trend Analysis Report: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), XPO Logistics Inc (NYSE:XPO) - Review Fortune (NASDAQ:MNTA) reviewfortune.com - August 4 at 6:35 PM
	Momenta reports 2Q loss (NASDAQ:MNTA) sg.finance.yahoo.com - August 4 at 6:35 PM